Bajaj Healthcare Q1 Performance: Robust Operational Growth and Return to Profitability

$BAJAJHCARE Bajaj Healthcare Ltd. has reported a strong performance for the quarter ended June 30, 2026. The pharmaceutical manufacturer—specializing in active pharmaceutical ingredients (APIs), formulations, and nutraceuticals—demonstrated solid year-over-year growth and successfully rebounded from a loss in the preceding quarter, driven by higher sales and expanded operating margins. Revenue from Operations: Grew by 11.3% to ₹165.6 crore, up from ₹148.8 crore in the corresponding quarter of the previous year. Net Profit (PAT): Consolidated Profit After Tax from continuing operations rose by 14.1% to ₹13.9 crore, compared to ₹12.2 crore last year. Operating Profit (EBITDA): Increased by 17.3% to ₹28.8 crore, up from ₹24.5 crore. EBITDA Margin: Expanded by 90 basis points to 17.4%, up from 16.5%, reflecting a clear improvement in operating profitability and cost efficiency. Sequential Recovery and Turnaround A central highlight for investors this quarter is the company's sequential recovery. Bajaj Healthcare posted a PAT of ₹13.9 crore against a net loss of ₹19.4 crore in the preceding March quarter. Revenue Momentum: Sequentially, revenue increased by 8.2% from ₹153.1 crore. Resolution of Exceptional Items: The March quarter's loss was heavily weighed down by a one-time exceptional expense of ₹33.2 crore. This was primarily due to the reversal of income recognized in an earlier period under a technical know-how arrangement, following delays caused by geopolitical instability in West Asia. The Q1 results indicate that the core business remains fundamentally sound absent these one-off geographical headwinds. Market Reaction Investors responded positively to the earnings beat and the return to profitability. Following the earnings announcement, shares of Bajaj Healthcare closed at ₹391 on the National Stock Exchange (NSE), registering a gain of 4.56% from the previous close.